Why did earnings fall so sharply despite revenue growth?

Medical costs rose faster than premiums. The consolidated MCR increased 470 basis points to 89.9%, reflecting elevated medical cost trends, the ongoing effects of Biden-era Medicare funding reductions, and changes to the Part D program under the Inflation Reduction Act. Operating costs also rose to 13.5% of revenue from 13.2% a year earlier, reflecting investments to support future growth.

Is the raised full-year guidance a sign the business is recovering?

The raised outlook (GAAP EPS of at least $14.90 and adjusted EPS of at least $16.25) suggests management has more confidence in 2025 results, and the MCR was in line with expectations set in Q2. However, Q3 profitability was still far below prior-year levels, so investors will want to see whether margins stabilize in the coming quarters and whether management delivers the 'accelerating growth' it cites for 2026.

Which segment is driving the earnings decline?

UnitedHealthcare's Q3 operating margin fell to 2.1% from 5.6%, with earnings from operations of $1.8B versus $4.2B. Optum's earnings from operations dropped to $2.5B from $4.5B. Within Optum, Optum Health was the largest drag, with operating earnings of $255M versus $2.2B, while Optum Rx earnings were flat at about $1.5B on higher revenue but lower margins.

How is the company's financial position and capital allocation?

Cash flow from operations was $5.9B in Q3, and the debt-to-capital ratio was steady at 44.1% even after the Amedisys acquisition closed on August 14, 2025. Through nine months, the company repurchased $5.5B in shares and paid $5.9B in dividends, while operating cash flow of $18.6B was down from $21.8B a year earlier. Net borrowings of $2.4B helped fund the gap.

What are the main risks flagged in the filing?

The forward-looking statements highlight risks including the ability to estimate and manage medical costs, changes to Medicare and CMS star ratings, risk adjustment data validation audits, DOJ legal actions related to Medicare participation, government investigations, cyberattacks, pharmacy care risks, and competitive pressures. The filing also notes the remaining sale of South American operations and the potential for goodwill impairment.

UNH 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 28, 2025. Cited figures are marked; the original filing is the authoritative source.

UnitedHealth Group (UNH) reported third quarter 2025 results on October 28, 2025, showing revenue growth alongside a sharp decline in profitability.

Consolidated revenues rose 12% year-over-year to $113.2 billion^a, driven by UnitedHealthcare (up 16% to $87.1 billion, led by Medicare & Retirement) and Optum (up 8% to $69.2 billion, led by Optum Rx). However, earnings from operations fell 50% to $4.3 billion and net margin compressed to 2.1% from 6.0%. GAAP diluted EPS was $2.59 versus $6.51 a year earlier, and adjusted EPS was $2.92 versus $7.15.

The medical care ratio rose 470 basis points to 89.9%, which management attributed to elevated medical cost trends, the effects of Biden-era Medicare funding reductions, and Inflation Reduction Act changes to the Part D program. Management said the MCR was in line with its second-quarter expectations and that medical reserve development was $80 million^b favorable. The key positive for investors is the raised full-year 2025 outlook: GAAP EPS of at least $14.90 and adjusted EPS of at least $16.25.

Cash flow from operations was strong at $5.9 billion^c, or 2.3x net income. The debt-to-capital ratio held at 44.1%, including the Amedisys acquisition that closed on August 14, 2025. Management framed the quarter as part of a path to 'durable and accelerating growth in 2026 and beyond,' but the margin deterioration, especially at Optum Health (operating margin of about 1%), is the central issue for investors weighing the durability of the recovery.

From a balance sheet and cash standpoint, total assets were $315.3 billion^d and equity was $101.6 billion at September 30, 2025. Nine-month operating cash flow was $18.6 billion, down from $21.8 billion a year earlier, while share repurchases ($5.5 billion) and dividends ($5.9 billion) were funded in part by net new borrowings of $2.4 billion. Optum Insight's contract backlog was stable at $32.1 billion, and membership growth continued, with UnitedHealthcare serving 50.1 million domestic consumers, up 795,000 year-over-year.

02—Key points

Key Highlights

Revenue up 12% YoY to $113.2B, with UnitedHealthcare up 16% to $87.1B and Optum up 8% to $69.2B.
Earnings from operations fell 50% YoY to $4.3B; net margin compressed to 2.1% from 6.0%.
GAAP diluted EPS of $2.59 (vs. $6.51 in Q3 2024); adjusted EPS of $2.92 (vs. $7.15).
Medical care ratio rose 470 bps to 89.9%, in line with Q2 2025 guidance, driven by elevated cost trends and Medicare funding/Part D IRA impacts.
Full-year 2025 outlook raised to GAAP EPS of at least $14.90 and adjusted EPS of at least $16.25.
Optum Health operating margin fell to 1% ($255M earnings from operations) from 8.3% a year earlier due to reimbursement pressure and elevated utilization.
Operating cash flow of $5.9B in Q3 (2.3x net income); debt-to-capital ratio steady at 44.1%.

03—Questions

Frequently Asked Questions

Why did earnings fall so sharply despite revenue growth?
Medical costs rose faster than premiums. The consolidated MCR increased 470 basis points to 89.9%, reflecting elevated medical cost trends, the ongoing effects of Biden-era Medicare funding reductions, and changes to the Part D program under the Inflation Reduction Act. Operating costs also rose to 13.5% of revenue from 13.2% a year earlier, reflecting investments to support future growth.
Is the raised full-year guidance a sign the business is recovering?
The raised outlook (GAAP EPS of at least $14.90 and adjusted EPS of at least $16.25) suggests management has more confidence in 2025 results, and the MCR was in line with expectations set in Q2. However, Q3 profitability was still far below prior-year levels, so investors will want to see whether margins stabilize in the coming quarters and whether management delivers the 'accelerating growth' it cites for 2026.
Which segment is driving the earnings decline?
UnitedHealthcare's Q3 operating margin fell to 2.1% from 5.6%, with earnings from operations of $1.8B versus $4.2B. Optum's earnings from operations dropped to $2.5B from $4.5B. Within Optum, Optum Health was the largest drag, with operating earnings of $255M versus $2.2B, while Optum Rx earnings were flat at about $1.5B on higher revenue but lower margins.
How is the company's financial position and capital allocation?
Cash flow from operations was $5.9B in Q3, and the debt-to-capital ratio was steady at 44.1% even after the Amedisys acquisition closed on August 14, 2025. Through nine months, the company repurchased $5.5B in shares and paid $5.9B in dividends, while operating cash flow of $18.6B was down from $21.8B a year earlier. Net borrowings of $2.4B helped fund the gap.
What are the main risks flagged in the filing?
The forward-looking statements highlight risks including the ability to estimate and manage medical costs, changes to Medicare and CMS star ratings, risk adjustment data validation audits, DOJ legal actions related to Medicare participation, government investigations, cyberattacks, pharmacy care risks, and competitive pressures. The filing also notes the remaining sale of South American operations and the potential for goodwill impairment.

04—Continue

← View all 8-K filings